Previous publications have reported that 70% of urate produced in humans is mainly regulated by the renal urate transport system [20], and in particular, the expression levels of cellular transporters OAT1 and URAT1 have recently been defined as potential therapeutic targets for the treatment of hyperuricemia [11]. Here, SLC22A6 is linked to hyperuricemia.